Matching articles for "Yaz"

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023;  (Issue 1676)
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • October 8, 2018;  (Issue 1557)
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-8 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • September 14, 2015;  (Issue 1477)
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in...
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rates of failure.
Med Lett Drugs Ther. 2015 Sep 14;57(1477):127-32 | Show Full IntroductionHide Full Introduction

In Brief: Warning about Drospirenone in Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • April 30, 2012;  (Issue 1389)
The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone (Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of...
The FDA has announced that combination hormonal contraceptives (CHCs) containing the synthetic progestin drospirenone (Yaz, Yasmin, Beyaz, Safyral, and others) may be associated with a higher risk of thromboembolism than CHCs containing other progestins.1

The new warning was based partly on an unpublished, FDA-funded, retrospective study that found a 1.7-times higher risk of venous thromboembolism among US women who used a CHC that contained drospirenone than among women whose CHC contained levonorgestrel, norgestimate or norethindrone as the progestin component.2 As with all retrospective studies, unknowable confounding factors, such as why doctors prescribed one progestin over the other, could have distorted the results.

All CHCs increase the risk of venous thromboembolism; whether the progestin component affects the risk has been controversial. The Medical Letter and several other reviews and consensus statements have found no convincing evidence of an increased risk with drospirenone.3-5

1. FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available at www.fda.gov/Drugs/DrugSafety/ucm299305.htm. Accessed April 23, 2012.

2. FDA. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at www.fda.gov/downloads/Drugs/DrugSafety/ucm277384. Accessed April 23, 2012.

3. Combination oral contraceptives and the risk of venous thromboembolism. Med Lett Drugs Ther 2010; 52:23.

4. RL Reid. Oral contraceptives and venous thromboembolism: pill scares and public health. J Obstet Gynaecol Can 2011; 33:1150.

5. L Manzoli et al. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 2012; 35: 191.

Download complete U.S. English article

Med Lett Drugs Ther. 2012 Apr 30;54(1389):33 | Show Full IntroductionHide Full Introduction

In Brief: An Oral Contraceptive with Folate

   
The Medical Letter on Drugs and Therapeutics • December 13, 2010;  (Issue 1353)
Six years after an FDA advisory committee recommended development of a combination tablet containing an oral contraceptive and folic acid,1 the FDA has approved Beyaz (Bayer), a combination of the oral...
Six years after an FDA advisory committee recommended development of a combination tablet containing an oral contraceptive and folic acid,1 the FDA has approved Beyaz (Bayer), a combination of the oral contraceptive Yaz2 with 451 mcg of levomefolate calcium, the primary metabolite of folic acid.3 According to the FDA, an unpublished double-blind, randomized U.S. trial in 379 healthy women 18-40 years old found that the combination increased serum folate levels. In an unpublished German study using a similar oral contraceptive/ levomefolate combination (summarized in the package insert), folate levels remained elevated for several weeks after levomefolate was stopped.4

The standard US diet provides 50-500 mcg of absorbable folate per day, but the bioavailability of folate in mixed diets varies. Folic acid in supplements is more bioavailable than folate in food.5 Supplementing the diet of women of childbearing age with 400 mcg of folic acid per day, the amount contained in most multivitamin preparations, has dramatically decreased the incidence of neural tube defects in their offspring.To effectively prevent neural tube defects, folic acid supplementation should be started at least one month before conception and continued through the first 2-3 months of pregnancy. Since incorrect or inconsistent use of oral contraceptives may account for as many as one million pregnancies in the US each year, all women capable of becoming pregnant should take a folic acid supplement.6,7

1. Folic acid supplementation to prevent neural tube defects. Med Lett Drugs Ther 2004; 46:17.

2. Three new oral contraceptives. Med Lett Drugs Ther 2006; 48:77.

3. Choice of contraceptives. Treat Guidel Med Lett 2010; 8:89.

4. FDA approves combination contraceptive containing a folate. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm227237.htm. Accessed October 5, 2010.

5. GP Oakley, Jr. Eat right and take a multivitamin. N Engl J Med 1998; 338:1060.

6. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:626.

7. AM Kaunitz. Oral contraceptive use, pregnancy intendedness and folic acid intake. FDA Advisory Committee for Reproductive Health Drugs meeting; December 15, 2003; Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/4002T1.DOC. Accessed November 3, 2010.

Download U.S. English
Med Lett Drugs Ther. 2010 Dec 13;52(1353):104 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • December 1, 2010;  (Issue 100)
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods...
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods available to women. Hormonal contraceptives, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rate of failure.
Treat Guidel Med Lett. 2010 Dec;8(100):89-96 | Show Full IntroductionHide Full Introduction

Combination Oral Contraceptives and the Risk of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • March 22, 2010;  (Issue 1334)
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing...
Combination oral contraceptives increase the risk of venous thromboembolism (VTE). Their benefits, in addition to preventing pregnancy, include lowering the risk of ovarian and endometrial cancer, reducing dysfunctional uterine bleeding and increasing serum hemoglobin concentrations. Are these benefits worth the risk? And are some combination oral contraceptives safer than others?
Med Lett Drugs Ther. 2010 Mar 22;52(1334):23-4 | Show Full IntroductionHide Full Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • December 1, 2007;  (Issue 64)
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or...
Transdermal, transvaginal and intrauterine hormone delivery systems have made highly effective contraceptive products more convenient to use. New oral contraceptive options include regimens with fewer or shorter hormone-free intervals.
Treat Guidel Med Lett. 2007 Dec;5(64):101-8 | Show Full IntroductionHide Full Introduction

Lybrel - A Continuous Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • July 30, 2007;  (Issue 1266)
Lybrel (Wyeth) is the first FDA-approved low-dose combination oral contraceptive taken 365 days a year without a placebo or pill-free interval. All tablets contain low doses of levonorgestrel (0.09 mg) and...
Lybrel (Wyeth) is the first FDA-approved low-dose combination oral contraceptive taken 365 days a year without a placebo or pill-free interval. All tablets contain low doses of levonorgestrel (0.09 mg) and ethinyl estradiol (20 mcg). Most oral contraceptives are packaged as a 21/7 cycle (21 days of active tablets and 7 days of placebo), resulting in 13 withdrawal bleeding episodes each year. Two formulations are taken for 24 days followed by 4 days of inert tablets (Yaz and Loestrin 24). Two others (Seasonique and Seasonale) have a 91-day cycle with only 4 withdrawal bleeds per year.
Med Lett Drugs Ther. 2007 Jul 30;49(1266):61-2 | Show Full IntroductionHide Full Introduction

Three New Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • September 25, 2006;  (Issue 1244)
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older...
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
Med Lett Drugs Ther. 2006 Sep 25;48(1244):77-8 | Show Full IntroductionHide Full Introduction